July 25, 2016 5:01 PM ET

Life Sciences Tools and Services

Company Overview of Patheon Holdings Coöperatief U.A.

Company Overview

Patheon Holdings Coöperatief U.A. provides outsourced pharmaceutical development and manufacturing services. The company offers a range of active pharmaceutical ingredient and finished drug product services, including formulation development, as well as clinical and commercial-scale manufacturing, packaging, and lifecycle management. It caters to small molecule and large molecule biological drugs sectors.Patheon Holdings Coöperatief U.A. was incorporated in 2013 and is based in Amsterdam, the Netherlands.

Herengracht 483

Amsterdam,  1017BT


Founded in 2013

8,800 Employees


31 20 622 3243

Key Executives for Patheon Holdings Coöperatief U.A.

Chief Executive Officer and Executive Director
Age: 57
Total Annual Compensation: $900.0K
Chief Financial Officer and Executive Vice President
Age: 60
Total Annual Compensation: $475.0K
President of Drug Substance Services
Age: 52
Total Annual Compensation: $492.0K
Executive Vice President of Corporate Development & Strategy and President of Banner Life Sciences
Age: 58
Total Annual Compensation: $444.2K
Senior Vice President of Quality and Continuous Improvement
Age: 55
Total Annual Compensation: $376.1K
Compensation as of Fiscal Year 2015.

Patheon Holdings Coöperatief U.A. Key Developments

Patheon Presents at BIO Trinity 2016, Apr-25-2016

Patheon Presents at BIO Trinity 2016, Apr-25-2016 . Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom.

Patheon Holdings Coöperatief U.A. Presents at BBC BD Boston, Mar-09-2016 10:30 AM

Patheon Holdings Coöperatief U.A. Presents at BBC BD Boston, Mar-09-2016 10:30 AM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: Michael E. Lytton, Executive Vice President of Corporate Development & Strategy and President of Banner Life Sciences.

Jaguar Animal Health Signs Crofelemer Formulation Development and Manufacturing Contract with Patheon

Jaguar Animal Health Inc. announced that it has signed a crofelemer formulation development and manufacturing contract with Patheon. Crofelemer is an active pharmaceutical ingredient (API) in Canalevia™, Jaguar’s prescription drug product candidate for the treatment of various forms of acute diarrhea in dogs. Under the terms of the contract, Patheon will provide enteric-coated crofelemer tablets for Jaguar for use in animals. The tablets will be used in Jaguar’s pivotal efficacy trial for Canalevia™, scheduled to begin in the fourth quarter of this year. Jaguar expects to use safety and effectiveness data from this trial in support of the initiation of the filing of a new animal drug application (NADA) with the FDA for Canalevia™ in 2016 for the indication of acute diarrhea in dogs.

Similar Private Companies By Industry

Company Name Region
Ampha B.V. Europe
Ascor Analyse Europe
Batavia Bioservices B.V. Europe
Brain Technology Institute Europe
Cardialysis B.V. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Patheon Holdings Coöperatief U.A., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.